title: Angiogenesis: models and modulators.
abstract: Angiogenesis in vivo is distinguished by four stages: subsequent to the transduction of signals to differentiate, stage 1 is defined as an altered proteolytic balance of the cell allowing it to digest through the surrounding matrix. These committed cells then proliferate (stage 2), and migrate (stage 3) to form aligned cords of cells. The final stage is the development of vessel patency (stage 4), generated by a coalescing of intracellular vacuoles. Subsequently, these structures anastamose and the initial flow of blood through the new vessel completes the process. We present and discuss how the available models most closely represent phases of in vivo angiogenesis. The enhancement of angiogenesis by hyaluronic acid fragments, transforming growth factor beta, tumor necrosis factor alpha, angiogenin, okadaic acid, fibroblast growth factor, interleukin 8, vascular endothelial growth factor, haptoglobin, and gangliosides, and the inhibition of the process by hyaluronic acid, estrogen metabolites, genestein, heparin, cyclosporin A, placental RNase inhibitor, steroids, collagen synthesis inhibitors, thrombospondin, fumagellin, and protamine are also discussed.
authors.affiliation: Hanson Center for Cancer Research, Institute of Medical and Veterinary Research, Adelaide, South Australia.
authors.forename: G W
authors.initials: GW
authors.lastname: Cockerill
authors.forename: J R
authors.initials: JR
authors.lastname: Gamble
authors.forename: M A
authors.initials: MA
authors.lastname: Vadas
mesh_terms: D000818:Animals; D002478:Cells, Cultured; D006131:Growth Inhibitors / Q000502:physiology; D006133:Growth Substances / Q000502:physiology; D006801:Humans; D009389:Neovascularization, Pathologic / Q000503:physiopathology*
chemical_list: D006131:Growth Inhibitors; D006133:Growth Substances